NASD · Healthcare · Biotechnology · USA
Geron Corp is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Geron Corp is a biopharmaceutical company that commercializes RYTELO, a telomerase inhibitor approved to treat adults with low- to intermediate-1 risk myelodysplastic syndromes. The company has launched RYTELO in the United States and the European Union following regulatory approvals. Geron is also developing imetelstat for other myeloid blood cancers, including myelofibrosis.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Geron Corp stock.
Undervalued: intrinsic value $1.34 per share, market price $1.00, margin of safety 25.3% (as of 2026-11-17).
A 4.2x revenue multiple, discounted for its losses, values the shares at $1.34; the price of $1.00 is 25% below that value.
17 more funds hold it; the full list is part of the paid plan.
12 more in this industry show a wider margin of safety.
GERN is undervalued (as of the 2026-11-17 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $1.34; the price of $1.00 is 25% below that value.
$1.34 per share (as of the 2026-11-17 close), against a market price of $1.00. That is a margin of safety of 25.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.